Skip to main content

Table 2 Association of circulating matrix metalloproteinase (MMP)-9 concentrations with laboratory and clinical variables in patients (n = 35) with systemic sclerosis

From: Elevated matrix metalloproteinase-9 in patients with systemic sclerosis

 

MMP-9 (ng/ml)a

Variable

Variable present (%)b

Variable absent

Modified Rodnan score >20

388 ± 29 (51)*

248 ± 38*

Esophageal involvementc

342 ± 33 (63)

304 ± 41

Interstitial lung diseased

321 ± 32 (60)

335 ± 41

Decrease of DLCO (<70%)e

350 ± 42 (43)

314 ± 34

Digital ulcer

364 ± 32 (43)

260 ± 35

Arthritis

333 ± 58 (14)

333 ± 28

Sicca syndrome

358 ± 40 (31)

320 ± 31

Antibodies to Scl-70f

348 ± 36 (37)

323 ± 45

Antibodies to centromere-Bf

288 ± 34 (37)

370 ± 39

  1. aConcentrations are presented as mean ± standard error of the mean. bPercentage of patients in whom the variable was clearly present; all other patients are included in the 'Variable absent' group. cDetermined by endoscopy and esophageal manometry. dEvaluated by chest x-ray and/or high-resolution computerized tomography, if necessary. eAbnormal diffusion capacity (DLCO, diffusion of carbon monoxide in the lung) on pulmonary function test was defined as below 70% of that in healthy controls. fMeasured by ELISA. *P = 0.006 in a comparison of the two groups (Mann–Whitney rank sum test). All other differences were not significant.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us